COMPANY INFO
Element Biosciences, Inc. is a biotechnology research company founded in 2017 by three scientists: Molly He, PhD (CEO & Co-Founder), Michael Previte, PhD (CTO & Co-Founder), and Matthew Kellinger, PhD (VP of Biochemistry & Co-Founder). The company, headquartered in San Diego, California, has approximately 400 employees and focuses on developing innovative genetic analysis tools, including the AVITI sequencing system, to provide affordable, high-quality sequencing for research and diagnostic markets. Their mission is to empower the scientific community with more freedom and flexibility to accelerate biological research and impact humanity. The official website is https://www.elementbiosciences.com, and the company operates in the biotechnology and healthcare technology industry.
Element Biosciences is a biotechnology research and healthcare technology company established in 2017. Headquartered in San Diego, California, Element Biosciences specializes in developing innovative genetic analysis tools, such as the AVITI sequencing system, aimed at providing affordable and high-quality sequencing solutions for research and diagnostic markets. With approximately 400 employees, the company’s founders—Molly He, PhD, Michael Previte, PhD, and Matthew Kellinger, PhD—have set a mission to empower the scientific community, driving advancements that accelerate biological discovery and impact global health.
Element Biosciences funding history demonstrates robust confidence from investors and strategic financial planning. The company has successfully raised a total of $678 million across seven funding rounds. Key milestones include significant capital infusions at each growth phase, with landmark Series C and D rounds supporting rapid scale-up, product commercialization, and the launch of advanced sequencing platforms. The funding strategy has focused on establishing a stable foundation for research, product development, and market expansion, with Element Biosciences investors representing leading venture capital firms and strategic partners in biotech and healthcare.
This Series D funding round was directed towards the commercialization of the AVITI benchtop DNA sequencer and the launch of the AVITI24 integrated biology platform, fueling continued rapid growth and ongoing product development.
Series C financing enabled the company to scale its operations and broaden market presence, helping to position Element Biosciences as a contender in competitive global sequencing markets.
This Series B round expedited the development of a new DNA sequencing platform and the integration of proprietary technologies, forming a foundation for the product’s subsequent commercialization.
An additional infusion of Series B capital was used to advance product development initiatives and support early stage company growth.
Series A funding provided the company with the resources necessary for initial product development and entry into the genetic sequencing market.
Wellington Management is a global investment management firm that led the Series D round, supporting Element Biosciences’ move into full commercialization and large-scale deployment of new sequencing technologies.
Acting as a strategic investor, Samsung Electronics has provided funding and industry insights to facilitate Element Biosciences’ growth in healthcare technology systems.
As a leading institutional investor, Janus Henderson Investors co-led the Series C round, helping to drive further operational scaling and market reach.
Logos Capital, specializing in life sciences investments, also co-led the Series C round and brought deep domain expertise to Element Biosciences' expansion efforts.
Fidelity Investments, a global financial services corporation, played a major role in the Series B round, securing crucial growth capital for advancing sequencing platform technology.
JSCapital invested in the Series B round, bringing operational expertise and resources to accelerate technology integration and market readiness.
Foresite Capital led the company’s initial Series A round, providing foundational financial support and guidance in early product development and commercialization.
Venrock, a well-known venture capital firm, participated in the Series A round, offering Element Biosciences both capital and venture guidance to launch its early products.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Element Biosciences funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.